![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC20A2 |
Gene summary for SLC20A2 |
![]() |
Gene information | Species | Human | Gene symbol | SLC20A2 | Gene ID | 6575 |
Gene name | solute carrier family 20 member 2 | |
Gene Alias | GLVR-2 | |
Cytomap | 8p11.21 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q08357 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6575 | SLC20A2 | LZE4T | Human | Esophagus | ESCC | 8.58e-28 | 1.02e+00 | 0.0811 |
6575 | SLC20A2 | LZE7T | Human | Esophagus | ESCC | 1.96e-08 | 4.58e-01 | 0.0667 |
6575 | SLC20A2 | LZE8T | Human | Esophagus | ESCC | 1.03e-08 | 4.51e-01 | 0.067 |
6575 | SLC20A2 | LZE20T | Human | Esophagus | ESCC | 9.95e-12 | 4.77e-01 | 0.0662 |
6575 | SLC20A2 | LZE22T | Human | Esophagus | ESCC | 5.01e-07 | 4.94e-01 | 0.068 |
6575 | SLC20A2 | LZE24T | Human | Esophagus | ESCC | 1.08e-38 | 1.22e+00 | 0.0596 |
6575 | SLC20A2 | LZE21T | Human | Esophagus | ESCC | 4.65e-06 | 3.78e-01 | 0.0655 |
6575 | SLC20A2 | P1T-E | Human | Esophagus | ESCC | 1.39e-12 | 7.47e-01 | 0.0875 |
6575 | SLC20A2 | P2T-E | Human | Esophagus | ESCC | 9.38e-11 | 3.16e-01 | 0.1177 |
6575 | SLC20A2 | P4T-E | Human | Esophagus | ESCC | 1.28e-28 | 8.39e-01 | 0.1323 |
6575 | SLC20A2 | P5T-E | Human | Esophagus | ESCC | 3.35e-22 | 3.26e-01 | 0.1327 |
6575 | SLC20A2 | P8T-E | Human | Esophagus | ESCC | 2.21e-15 | 2.93e-01 | 0.0889 |
6575 | SLC20A2 | P9T-E | Human | Esophagus | ESCC | 3.37e-26 | 6.29e-01 | 0.1131 |
6575 | SLC20A2 | P10T-E | Human | Esophagus | ESCC | 2.26e-39 | 6.88e-01 | 0.116 |
6575 | SLC20A2 | P11T-E | Human | Esophagus | ESCC | 2.36e-10 | 3.49e-01 | 0.1426 |
6575 | SLC20A2 | P12T-E | Human | Esophagus | ESCC | 6.92e-51 | 1.08e+00 | 0.1122 |
6575 | SLC20A2 | P15T-E | Human | Esophagus | ESCC | 1.30e-79 | 1.94e+00 | 0.1149 |
6575 | SLC20A2 | P16T-E | Human | Esophagus | ESCC | 6.75e-21 | 4.40e-01 | 0.1153 |
6575 | SLC20A2 | P17T-E | Human | Esophagus | ESCC | 1.07e-07 | 2.82e-01 | 0.1278 |
6575 | SLC20A2 | P19T-E | Human | Esophagus | ESCC | 4.11e-02 | 3.43e-01 | 0.1662 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001603210 | Cervix | CC | viral process | 109/2311 | 415/18723 | 5.40e-15 | 6.46e-12 | 109 |
GO:001905810 | Cervix | CC | viral life cycle | 87/2311 | 317/18723 | 2.20e-13 | 1.20e-10 | 87 |
GO:005212610 | Cervix | CC | movement in host environment | 52/2311 | 175/18723 | 7.03e-10 | 8.76e-08 | 52 |
GO:004440910 | Cervix | CC | entry into host | 47/2311 | 151/18723 | 8.45e-10 | 1.03e-07 | 47 |
GO:005170110 | Cervix | CC | biological process involved in interaction with host | 57/2311 | 203/18723 | 1.18e-09 | 1.41e-07 | 57 |
GO:004671810 | Cervix | CC | viral entry into host cell | 44/2311 | 144/18723 | 5.47e-09 | 5.03e-07 | 44 |
GO:004440310 | Cervix | CC | biological process involved in symbiotic interaction | 71/2311 | 290/18723 | 7.94e-09 | 6.98e-07 | 71 |
GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
GO:0019058 | Colorectum | AD | viral life cycle | 119/3918 | 317/18723 | 6.18e-12 | 8.23e-10 | 119 |
GO:0044403 | Colorectum | AD | biological process involved in symbiotic interaction | 99/3918 | 290/18723 | 1.02e-07 | 4.93e-06 | 99 |
GO:0051701 | Colorectum | AD | biological process involved in interaction with host | 73/3918 | 203/18723 | 5.08e-07 | 1.88e-05 | 73 |
GO:0052126 | Colorectum | AD | movement in host environment | 63/3918 | 175/18723 | 2.85e-06 | 8.11e-05 | 63 |
GO:0046718 | Colorectum | AD | viral entry into host cell | 51/3918 | 144/18723 | 3.99e-05 | 7.16e-04 | 51 |
GO:0044409 | Colorectum | AD | entry into host | 51/3918 | 151/18723 | 1.60e-04 | 2.21e-03 | 51 |
GO:0015698 | Colorectum | AD | inorganic anion transport | 52/3918 | 180/18723 | 6.83e-03 | 4.22e-02 | 52 |
GO:00160324 | Colorectum | FAP | viral process | 114/2622 | 415/18723 | 3.00e-13 | 2.63e-10 | 114 |
GO:00190584 | Colorectum | FAP | viral life cycle | 81/2622 | 317/18723 | 2.97e-08 | 2.64e-06 | 81 |
GO:00444034 | Colorectum | FAP | biological process involved in symbiotic interaction | 66/2622 | 290/18723 | 3.47e-05 | 7.64e-04 | 66 |
GO:0035725 | Colorectum | FAP | sodium ion transmembrane transport | 44/2622 | 178/18723 | 9.31e-05 | 1.60e-03 | 44 |
GO:00521264 | Colorectum | FAP | movement in host environment | 42/2622 | 175/18723 | 2.64e-04 | 3.60e-03 | 42 |
Page: 1 2 3 4 5 6 7 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC20A2 | SNV | Missense_Mutation | c.985N>A | p.Gly329Ser | p.G329S | Q08357 | protein_coding | tolerated(0.14) | probably_damaging(0.916) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC20A2 | SNV | Missense_Mutation | c.1142G>A | p.Arg381His | p.R381H | Q08357 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC20A2 | SNV | Missense_Mutation | c.1142G>A | p.Arg381His | p.R381H | Q08357 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-D8-A1XY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | tamoxiphen | SD | |
SLC20A2 | SNV | Missense_Mutation | novel | c.1216G>A | p.Asp406Asn | p.D406N | Q08357 | protein_coding | tolerated(0.19) | benign(0.201) | TCGA-E2-A2P6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
SLC20A2 | SNV | Missense_Mutation | novel | c.608C>T | p.Ala203Val | p.A203V | Q08357 | protein_coding | deleterious(0.01) | possibly_damaging(0.897) | TCGA-LL-A5YO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
SLC20A2 | SNV | Missense_Mutation | rs777147006 | c.922N>T | p.Arg308Trp | p.R308W | Q08357 | protein_coding | deleterious(0.01) | possibly_damaging(0.849) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SLC20A2 | SNV | Missense_Mutation | novel | c.1169C>T | p.Thr390Ile | p.T390I | Q08357 | protein_coding | deleterious(0.03) | probably_damaging(0.991) | TCGA-UC-A7PG-06 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
SLC20A2 | SNV | Missense_Mutation | novel | c.1242G>C | p.Glu414Asp | p.E414D | Q08357 | protein_coding | tolerated(0.13) | benign(0.174) | TCGA-WL-A834-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
SLC20A2 | SNV | Missense_Mutation | rs376447185 | c.1850N>A | p.Arg617His | p.R617H | Q08357 | protein_coding | tolerated(0.23) | benign(0.015) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC20A2 | SNV | Missense_Mutation | rs387906652 | c.1802N>T | p.Ser601Leu | p.S601L | Q08357 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-AY-A69D-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |